-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in Hong Kong stocks | Yingpai Pharmaceutical-B (07630) opened nearly 15% higher, and senapalil was approved by the European Commission for listing to actively promote related global clinical development

Zhitongcaijing·11/17/2026 01:33:13
Listen to the news

The Zhitong Finance App learned that Yingpai Pharmaceutical-B (07630) was nearly 15% higher. As of press release, it had risen 14.96% to HK$10.72, with a turnover of HK$3.554 million.

According to the news, on November 17, Yingpai Pharmaceutical-B announced that the innovative drug Senapali (Chinese product name: Pysuning®, overseas product name: Sepalna®) has officially obtained a final decision from the European Commission (EC) to approve it for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. The approval was made by the European Commission (EC) based on positive opinions from the European Medicines Agency (EMA) Committee on Medicines for Human Use (CHMP). Since then, senapalil has become the first first-line maintenance PARP inhibitor for advanced ovarian cancer in China to be approved and marketed by the European Union, marking another breakthrough for domestically produced innovative drugs targeting ovarian cancer in the European market.

Sepalna® (Sepalna ®) is a novel, highly active PARP1/2 inhibitor independently developed by our company. Its unique molecular structure ensures excellent target selectivity and a wide safety window. Senapalil capsules were approved by China's National Drug Administration in January 2025 to be used as first-line maintenance treatment for adult patients with advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have achieved complete or partial remission from platinum chemotherapy, and were then included in the “National Medical Insurance Drug List” in December 2025. The company is actively promoting clinical and regulatory development of senapalil around the world. At the same time, the company is also promoting the life cycle management of senapalil, exploring opportunities for combined treatment, and expanding it to multiple indications.